To further assess the therapeutic potential of targeting MFRN1, our future studies will determine whether the increased expression of MFRN1 also contributes to the radiation-induced effects on labile iron and ETC function that we found to promote radioresistance in glioma cells. Here, SLC25A37 is linked to central nervous system cancer.